Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analogues.

@article{Jaroszewicz2011HepatitisBS,
  title={Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analogues.},
  author={Jerzy Jaroszewicz and Huy Ho and Antoaneta Angelova Markova and Katja Deterding and Karsten Wursthorn and Sandra Schulz and Claus-Thomas Bock and Hans L Tillmann and Michael P. Manns and Heiner Wedemeyer and Markus Cornberg},
  journal={Antiviral therapy},
  year={2011},
  volume={16 6},
  pages={915-24}
}
BACKGROUND Hepatitis B surface antigen (HBsAg) loss is the ultimate goal of antiviral therapy and its prediction may be important for treatment individualization. Quantitative HBsAg (qHBsAg) has been shown to predict response to interferon-α, but few studies have analysed qHBsAg during treatment with nucleoside/nucleotide analogues (NAs). Serum interferon-inducible protein-10 (IP-10) has been associated with treatment response in hepatitis C, but data in chronic hepatitis B are lacking. Here… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 32 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 38 references

Similar Papers

Loading similar papers…